Telmisartan/hydrochlorothiazide: a new fixed dose combination (Q36124874)

12 August 2017

1 reference

title

Telmisartan/hydrochlorothiazide: a new fixed dose combination (English)

1 reference

12 August 2017

Marc Maillard

1

1 reference

12 August 2017

Michel Burnier

series ordinal

2

1 reference

12 August 2017

publication date

1 May 2005

1 reference

Expert Review of Cardiovascular Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

3

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

375-386

1 reference

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Lessons from trials in hypertensive type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Localization of the gene for X-linked Alport's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Gender difference in the response to an angiotensin-converting enzyme inhibitor and a diuretic in hypertensive patients of African descent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension--a randomised ABPM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Cardiovascular drugs and serum uric acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Telmisartan: a review of its use in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Reasons for not intensifying antihypertensive treatment (RIAT): a primary care antihypertensive intervention study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Yet more hypertension guidelines: what do they add?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin-system gene expression and cardiovascular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

Practice Guidelines For Primary Care Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.3.375

21 January 2018

Identifiers

DOI

10.1586/14779072.3.3.375

1 reference

12 August 2017

1 reference